Skip Nav Destination
Issues
1 July 2022
-
Cover Image
Cover Image
Representative multiplex immunostaining of tumor tissue from a MAPK-activated pleomorphic xanthoastrocytoma (PXA), demonstrating abundant tumor-associated microglia/macrophages including Iba1+ (green), CD163+ (red), and dual positive (yellow) cells. For details, see the article by Kumar and colleagues on page 2898 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR Drug Updates
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation
Sandra J. Casak; Shan Pradhan; Lola A. Fashoyin-Aje; Yi Ren; Yuan-Li Shen; Yuan Xu; Edwin Chiu Yuen Chow; Ye Xiong; Jeanne Fourie Zirklelbach; Jiang Liu; Rosane Charlab; William F. Pierce; Nataliya Fesenko; Julia A. Beaver; Richard Pazdur; Paul G. Kluetz; Steven J. Lemery
Review
Clinical Trials: Targeted Therapy
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia
Marina Konopleva; Michael J. Thirman; Keith W. Pratz; Jacqueline S. Garcia; Christian Recher; Vinod Pullarkat; Hagop M. Kantarjian; Courtney D. DiNardo; Monique Dail; Yinghui Duan; Brenda Chyla; Jalaja Potluri; Catherine L. Miller; Andrew H. Wei
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations
Daniel A. Pollyea; Courtney D. DiNardo; Martha L. Arellano; Arnaud Pigneux; Walter Fiedler; Marina Konopleva; David A. Rizzieri; B. Douglas Smith; Atsushi Shinagawa; Roberto M. Lemoli; Monique Dail; Yinghui Duan; Brenda Chyla; Jalaja Potluri; Catherine L. Miller; Hagop M. Kantarjian
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study
Vivek Subbiah; Irene Braña; Alessandra Longhi; Valentina Boni; Jean-Pierre Delord; Ahmad Awada; Pascaline Boudou-Rouquette; John Sarantopoulos; Geoffrey I. Shapiro; Anthony Elias; Ravin Ratan; Cristian Fernandez; Carmen Kahatt; Martin Cullell-Young; Mariano Siguero; Ali Zeaiter; Sant P. Chawla
Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFNα ± Bevacizumab: Results from CALGB 90206 (Alliance)
Andrew B. Nixon; Susan Halabi; Yingmiao Liu; Mark D. Starr; John C. Brady; Ivo Shterev; Bin Luo; Herbert I. Hurwitz; Phillip G. Febbo; Brian I. Rini; Himisha Beltran; Eric J. Small; Michael J. Morris; Daniel J. George
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
Andrew B. Nixon; Alexander B. Sibley; Yingmiao Liu; Ace J. Hatch; Chen Jiang; Flora Mulkey; Mark D. Starr; John C. Brady; Donna Niedzwiecki; Alan P. Venook; Luis Baez-Diaz; Heinz-Josef Lenz; Bert H. O'Neil; Federico Innocenti; Jeffrey A. Meyerhardt; Eileen M. O'Reilly; Kouros Owzar; Herbert I. Hurwitz
A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent
Mark C. Markowski; Ronald Tutrone; Christopher Pieczonka; K. Gary Barnette; Robert H. Getzenberg; Domingo Rodriguez; Mitchell S. Steiner; Daniel R. Saltzstein; Mario A. Eisenberger; Emmanuel S. Antonarakis
Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection
Xiuning Le; Frederico O. Gleber-Netto; M. Laura Rubin; Yun Qing; Robyn Du; Merrill Kies; George Blumenschein, Jr; Charles Lu; Faye M. Johnson; Diana Bell; Jeff Lewis; Jiexin Zhang; Lei Feng; Kaye Wilson; Kathrina Marcelo-Lewis; Jing Wang; Lawrence Ginsberg; Maura Gillison; J. Jack Lee; Funda Meric-Berstam; Gordon B. Mills; William N. William, Jr; Jeffrey N. Myers; Curtis R. Pickering
Clinical Trials: Immunotherapy
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
Li Chen; Yi-Zhou Jiang; Song-Yang Wu; Jiong Wu; Gen-Hong Di; Guang-Yu Liu; Ke-Da Yu; Lei Fan; Jun-Jie Li; Yi-Feng Hou; Zhen Hu; Can-Ming Chen; Xiao-Yan Huang; A-Yong Cao; Xin Hu; Shen Zhao; Xiao-Yan Ma; Ying Xu; Xiang-Jie Sun; Wen-Jun Chai; Xiaomao Guo; Xizi Chen; Yanhui Xu; Xiao-Yu Zhu; Jian-Jun Zou; Wen-Tao Yang; Zhong-Hua Wang; Zhi-Ming Shao
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study
Joleen M. Hubbard; Enikő R. Tőke; Roberto Moretto; Rondell P. Graham; Hagop Youssoufian; Orsolya Lőrincz; Levente Molnár; Zsolt Csiszovszki; Jessica L. Mitchell; Jaclynn Wessling; József Tóth; Chiara Cremolini
Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Mingzhi Zhang; Dan Chen; Xiaorui Fu; Huimin Meng; Feifei Nan; Zhenchang Sun; Hui Yu; Lei Zhang; Ling Li; Xin Li; Xinhua Wang; Min Wang; Fengtao You; Zhaoming Li; Yu Chang; Zhiyuan Zhou; Jiaqin Yan; Jiwei Li; Xiaolong Wu; Yu Wang; Yinyan Wang; Shufen Xiang; YuSheng Chen; Guifang Pan; Hanying Xu; Bozhen Zhang; Lin Yang
Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data
Thanh G.N. Ton; Navdeep Pal; Huong Trinh; Sami Mahrus; Michael T. Bretscher; Robson J.M. Machado; Natalia Sadetsky; Nayan Chaudhary; Michael W. Lu; Gregory J. Riely
Precision Medicine and Imaging
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Parvathi Sudha; Aarif Ahsan; Cody Ashby; Tasneem Kausar; Akhil Khera; Mohammad H. Kazeroun; Chih-Chao Hsu; Lin Wang; Evelyn Fitzsimons; Outi Salminen; Patrick Blaney; Magdalena Czader; Jonathan Williams; Mohammad I. Abu Zaid; Naser Ansari-Pour; Kwee L. Yong; Frits van Rhee; William E. Pierceall; Gareth J. Morgan; Erin Flynt; Sarah Gooding; Rafat Abonour; Karthik Ramasamy; Anjan Thakurta; Brian A. Walker
Translational Cancer Mechanisms and Therapy
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer
Clinton Yam; Nour Abuhadra; Ryan Sun; Beatriz E. Adrada; Qing-Qing Ding; Jason B. White; Elizabeth E. Ravenberg; Alyson R. Clayborn; Vicente Valero; Debu Tripathy; Senthilkumar Damodaran; Banu K. Arun; Jennifer K. Litton; Naoto T. Ueno; Rashmi K. Murthy; Bora Lim; Luis Baez; Xiaoxian Li; Aman U. Buzdar; Gabriel N. Hortobagyi; Alistair M. Thompson; Elizabeth A. Mittendorf; Gaiane M. Rauch; Rosalind P. Candelaria; Lei Huo; Stacy L. Moulder; Jeffrey T. Chang
Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial
Charlotte Duch Lynggaard; Christian Grønhøj; Siri B. Jensen; Robin Christensen; Lena Specht; Elo Andersen; Tobias T. Andersen; Urszula M. Ciochon; Gulla S. Rathje; Adam E. Hansen; Helene Stampe; Anne Fischer-Nielsen; Christian von Buchwald
CXCL14 Promotes a Robust Brain Tumor-Associated Immune Response in Glioma
Anupam Kumar; Esraa Mohamed; Schuyler Tong; Katharine Chen; Joydeep Mukherjee; Yunita Lim; Cynthia M. Wong; Zoe Boosalis; Anny Shai; Russell O. Pieper; Nalin Gupta; Arie Perry; Andrew W. Bollen; Annette M. Molinaro; David A. Solomon; Joseph T.C. Shieh; Joanna J. Phillips
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
Zhao Cheng; Hasan Mirza; Darren P. Ennis; Philip Smith; Lena Morrill Gavarró; Chishimba Sokota; Gaia Giannone; Theodora Goranova; Thomas Bradley; Anna Piskorz; Michelle Lockley; For the BriTROC-1 Investigators; Baljeet Kaur; Naveena Singh; Laura A. Tookman; Jonathan Krell; Jacqueline McDermott; Geoffrey Macintyre; Florian Markowetz; James D. Brenton; Iain A. McNeish
A Paradigm of Cancer Immunotherapy Based on 2-[18F]FDG and Anti–PD-L1 mAb Combination to Enhance the Antitumor Effect
Xuejun Wen; Changrong Shi; Xinying Zeng; Liang Zhao; Lanlin Yao; Zhida Liu; Lixia Feng; Deliang Zhang; Jinxiong Huang; Yesen Li; Qin Lin; Haojun Chen; Rongqiang Zhuang; Xiaoyuan Chen; Xianzhong Zhang; Zhide Guo
Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
Virginia Aragon-Sanabria; Anusha Aditya; Li Zhang; Feng Chen; Barney Yoo; Tianye Cao; Brian Madajewski; Rachel Lee; Melik Z. Turker; Kai Ma; Sebastien Monette; Peiming Chen; Jing Wu; Shutian Ruan; Michael Overholtzer; Pat Zanzonico; Charles M. Rudin; Cameron Brennan; Ulrich Wiesner; Michelle S. Bradbury
Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade
Wei Wang; Taja Lozar; Athena E. Golfinos; Denis Lee; Ellery Gronski; Ella Ward-Shaw; Mitchell Hayes; Justine Y. Bruce; Randall J. Kimple; Rong Hu; Paul M. Harari; Jin Xu; Aysenur Keske; Paul M. Sondel; Megan B. Fitzpatrick; Huy Q. Dinh; Paul F. Lambert
Corrections
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
Florence Atrafi; Oliver Boix; Vivek Subbiah; Jennifer R. Diamond; Sant P. Chawla; Anthony W. Tolcher; Patricia M. LoRusso; Joseph P. Eder; Martin Gutierrez; Kumar Sankhala; Prabhu Rajagopalan; Isabelle Genvresse; Simon Langer; Ron H.J. Mathijssen; Jaap Verweij; Ingmar Bruns; Martijn P. Lolkema
Editor's Notes
Editor's Note: Dasatinib Plus Nutlin-3 Shows Synergistic Antileukemic Activity in Both p53wild-type and p53mutated B Chronic Lymphocytic Leukemias by Inhibiting the Akt Pathway
Giorgio Zauli; Rebecca Voltan; Raffaella Bosco; Elisabetta Melloni; Sandra Marmiroli; Gian Matteo Rigolin; Antonio Cuneo; Paola Secchiero
Advertisement
